Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: KEGG:D05575 (
Pramipexole
)
205
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Dopamine agonists are effective in reversing the motor symptoms of Parkinson's disease (PD). They have also shown that they can delay or prevent the onset of motor complications associated with levodopa use. Recent attention has focused on the possible role for dopamine agonists in neuroprotection. Numerous studies have demonstrated that a variety of dopamine agonists can protect dopaminergic neuronal function in several toxin model systems.
Pramipexole
in particular has shown efficacy in reducing toxicity to MPTP,
MPP
, rotenone and 6-hydroxydopamine. Recent studies in early PD using imaging parameters as a surrogate marker of dopaminergic neuronal integrity have shown that pramipexole and ropinirole can apparently retard the rate of cell loss. These observations are of considerable interest, but additional studies are required to confirm a neuroprotective function for these dopamine agonists.
...
PMID:Dopamine agonists and neuroprotection in Parkinson's disease. 1246 16
Pramipexole
(
PPX
) is a common drug for the treatment of Parkinson's disease. However, the mechanism allows
PPX
in the progression of Parkinson's disease remains largely unknown. This study aimed to investigate the role of
PPX
in 1-Methyl-4-phenylpyridinium (
MPP
+
)-treated neuroblastoma cells and explore the interaction between
PPX
and miR-494-3p/brain derived neurotrophic factor (BDNF) axis. SK-N-SH and CHP 212 cells challenged by
MPP
+
were used as cellular model of Parkinson's disease and incubated with
PPX
. The expression levels of miR-494-3p and BDNF were measured by quantitative real-time polymerase chain reaction or western blot. Neurotoxicity was investigated by cell apoptosis, inflammatory response and oxidative stress. The target association between miR-494-3p and BDNF was confirmed by luciferase reporter and RNA immunoprecipitation assays. miR-494-3p expression was increased and BDNF level was decreased in
MPP
+
-treated SK-N-SH and CHP 212 cells, which were reversed by introduction of
PPX
.
Pramipexole
attenuated cell apoptosis, inflammatory response and oxidative stress in
MPP
+
-treated SK-N-SH and CHP 212 cells. Knockdown of miR-494-3p also suppressed neurotoxicity induced by
MPP
+
in SK-N-SH and CHP 212 cells. BDNF was validated as a target of miR-494-3p and its silence abated the suppressive effect of miR-494-3p on
MPP
+
-induced neurotoxicity. Moreover, addition of miR-494-3p and silence of BDNF mitigated the effect of
PPX
on
MPP
+
-induced neurotoxicity.
PPX
inhibited
MPP
+
-induced neurotoxicity in SK-N-SH and CHP 212 cells by decreasing miR-494-3p and increasing BDNF, indicating the potential therapeutic effect of
PPX
on Parkinson's disease.
...
PMID:Pramipexole Inhibits MPP
+
-Induced Neurotoxicity by miR-494-3p/BDNF. 3181 58
